This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Iressa Versus Vinorelbine (INVITE)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: November 20, 2005
Last updated: April 22, 2009
Last verified: April 2009
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.

Condition Intervention Phase
Non-Small-Cell Lung Carcinoma Drug: Gefitinib Drug: Vinorelbine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To compare ZD1839 and vinorelbine in terms of progression free survival

Secondary Outcome Measures:
  • To compare ZD1839 and vinorelbine in terms of pulmonary symptom improvement weekly for 18 weeks.
  • To compare ZD1839 and vinorelbine in terms of quality of life 3 weekly for 18 weeks then 6 weekly.
  • To compare ZD1839 and vinorelbine in terms of adverse event profile continuous monitoring.
  • To compare ZD1839 and vinorelbine in terms of overall objective tumour response rate (complete response and partial response) 6 weekly to progression.
  • To compare ZD1839 and vinorelbine in terms of overall survival (time to death) continuous monitoring

Estimated Enrollment: 192
Study Start Date: July 2004
Study Completion Date: February 2006

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed NSCLC and willing to provide paraffin embedded tumour tissue
  • NSCLC - locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy chemonaïve, life expectancy of 12 weeks
  • WHO Performance status <= 2

Exclusion Criteria:

  • Newly diagnosed CNS metastases
  • Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity.
  • Hypersensitivity to ZD1839 or intravenous vinorelbine
  • Prior treatment with EGFR inhibitors
  • Other co-existing malignancies
  • ALT/AST >2.5 x ULRR
  • ANC < 2.0 x 10^9/L or platelets < 100 x 10^9/L
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00256711

  Show 56 Study Locations
Sponsors and Collaborators
Study Director: AstraZeneca Iressa Medical Science Director, MD AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00256711     History of Changes
Other Study ID Numbers: D791AC00001
Study First Received: November 20, 2005
Last Updated: April 22, 2009

Keywords provided by AstraZeneca:
Locally advanced or metastatic NSCLC.
Stage IIIb or Stage IV lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on September 19, 2017